Journal of Blood Disorders & Transfusion

PTEN status and Akt phosphorylation: Implications for the rituximab-resistance in B-cell lymphoma

7^th World Hematologists Congress

May 08-09, 2017 Barcelona, Spain

Jingjing Wu

First Affiliated Hospital of Zhengzhou University, China

Posters & Accepted Abstracts: J Blood Disord Transfus

Abstract:

Rituximab has been widely used in clinical practice for the treatment of B-cell malignancies, but the majority of patients retreated with rituximab will eventually relapse with variable degrees of resistant disease. There is an urgent need to explore the mechanisms of resistance to rituximab in non�??Hodgkin�??s lymphoma (NHL), and to develop therapeutic strategies to overcome resistance. Herein, we successfully set up three types of rituximab-resistant B lymphoma cell lines with different malignancy grade, and demonstrate that phosphatase and tensin homolog (PTEN) is low expressed in the rituximab-resistant cell lines. Furthermore, we report that reduced PTEN expression correlated with resistance to rituximab and inhibited tumor cell apoptosis through activation of Akt phosphorylation. Restoration of PTEN expression resulted in re-sensitization of resistant cells to rituximab through modulation of apoptosis by suppressing the p-Akt in the PI3K/Akt signaling pathway. Overall, our findings demonstrate a novel mechanism of rituximab-resistance by the involvement of PTEN status and Akt phosphorylation in three different types of rituximab-resistant B lymphoma cell lines, which may be new predictive markers for response to rituximab and provide new insights for reversing rituximab resistance in B-cell lymphoma.

Biography :

Email: wjjing1205@163.com